Stage III Solid Tumors, Stage IV Solid Tumors
Conditions
Brief summary
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Interventions
DIAGNOSTIC_TESTComprehensive molecular panel test
Lab test
OTHEREORTC QLQ-30
Quality of life questionnaire
Sponsors
Caris Life Sciences
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have given informed consent in accordance with the methods and procedures of this study * Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care * Patients who have not received treatment related to his/her cancer * Patients who are willing to sign a release of medical records to the research team * Male and female patients ≥18 years of age * Patients under oncology care of a participating site * Sufficient clinical status for collection of biospecimen samples within usual care * Patients who have insurance coverage for CMT
Exclusion criteria
* Patients considered minors in the jurisdiction where the protocol is conducted. * Patients who are prisoners and pregnant women. * Patients who cannot provide consent and did not sign a power of attorney.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30) | 2 years | The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare the proportion of patients enrolling in clinical trials | 2 years | To compare the proportion of enrolling in clinical trials between cancers patients who received the CMT versus cancer patients with no CMT. |
Countries
United States
Contacts
Primary ContactMihran H Shirinian, MD
Backup ContactLily Villalobos, MHA
Outcome results
None listed